+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Central Lab Market Size, Share & Trends Analysis Report by Service (Genetic Services, Biomarker Services), End-use (Pharmaceutical Companies, Biotechnology Companies), Region, and Segment Forecasts, 2024-2030

  • PDF Icon

    Report

  • 200 Pages
  • December 2023
  • Region: Global
  • Grand View Research
  • ID: 5649359
The global central lab market size is expected to reach USD 5.05 billion by 2030, expanding at a CAGR of 6.44% from 2024 to 2030. It is estimated to register a CAGR of 6.50% during the forecast period, driven by the increasing investment in R&D and increased focus of sponsors & investigators on reducing research costs. The outsourcing of central lab work is a significant factor driving the market growth.

Outsourcing central lab work is a rising trend in the clinical trial industry, which is expected to create lucrative business opportunities for central labs. The investigators and sponsors outsource ~80% of the central lab work and prefer the labs that provide end-to-end integrated services.

Investment in R&D has witnessed a surge in past years, which can be attributed to the enhanced focus on the pharmaceutical industry during the pandemic. As we enter the third year of the pandemic, investment in science has enhanced the pipeline and several clinical trials have been initiated. Over the pandemic, activity in interventional studies grew steadily. The pharmaceutical industry developed a new way of conducting trials for the management of ongoing clinical trials during the pandemic.

The pandemic has also created new growth opportunities, with an increasing focus on mRNA vaccine development and investigations for several COVID-19 treatment options. However, sample handling, supply chain, and logistics play a significant role in the sample sent to clinical labs. These samples are highly sensitive and require fast logistics with temperature control, thereby maintaining sample stability to get the most accurate results.

The rise of small- and medium-scale central laboratories is intensifying the competition globally. The presence of small- and medium-scale central labs is highly prominent in developing regions such as the Asia-Pacific. These laboratories are becoming critical in the management of clinical trials globally owing to the availability of central laboratory services at 20%-35% lower prices, when compared to Europe and the U.S. Furthermore, the lower cost of conducting clinical trials in the developing economies facilitates the selection of central laboratories present in these regions, which can be attributed to lower logistic costs and presence near the trial location.

Central Lab Market Report Highlights

  • The genetic services segment is anticipated to grow at the fastest growth rate, owing to the increasing significance of genetic analysis in clinical studies
  • Strategic acquisitions are one of the factors influencing the changing dynamics of the market. For instance, players are acquired by medium and large-scale enterprises for enhancing their global reach and entering new business segments
  • Pharmaceutical companies held the largest market share by end-use, attributable to an increasing number of interventional studies and investment into research
  • North America dominated the global market in 2023, the increasing need for genetic testing in clinical trials related to personalized healthcare in disease areas, such as diabetes & cancers
  • Key players in the market include ACM Global Laboratories, Labconnect, Cerba Research, Eurofins Scientific, Medicover Integrated Clinical Services, and Versiti

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation
1.1.1. Market Definitions
1.2. Objectives
1.2.1. Objective - 1
1.2.2. Objective - 2
1.2.3. Objective - 3
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Internal database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.8. List Of Secondary Sources
1.9. List of Abbreviations
1.10. List of Primary Sources
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers
3.4.1. Rising R&D investment in clinical trial
3.4.2. Escalating demand for novel drugs
3.4.3. Outsourcing of central lab work
3.4.4. Reducing the cost of drug research
3.5. Market Restraint Analysis
3.5.1. Logistics and sample handling
3.6. Business Environment Analysis
3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.6.2. Porter’s Five Forces Analysis
3.6.3. COVID-19 Impact Analysis
Chapter 4. Service Business Analysis
4.1. Central Lab Market: Service Movement Analysis
4.2. Genetic Services
4.2.1. Genetic Services Central Lab Market, 2018-2030 (USD Million)
4.3. Biomarker Services
4.3.1. Biomarker Services Central Lab Market, 2018-2030 (USD Million)
4.4. Microbiology Services
4.4.1. Microbiology Services Central Lab Market, 2018-2030 (USD Million)
4.5. Anatomic Pathology/Histology
4.5.1. Anatomic Pathology/Histology Central Lab Market, 2018-2030 (USD Million)
4.6. Specimen Management and Storage
4.6.1. Specimen Management and Storage Central Lab Market, 2018-2030 (USD Million)
4.7. Special Chemistry Services
4.7.1. Special Chemistry Services Central Lab Market, 2018-2030 (USD Million)
4.8. Others
4.8.1. Others Central Lab Market, 2018-2030 (USD Million)
Chapter 5. End Use Business Analysis
5.1. Central Lab Market: End-Use Movement Analysis
5.2. Pharmaceutical Companies
5.2.1. Pharmaceutical Companies Market, 2018-2030 (USD Million)
5.3. Biotechnology Companies
5.3.1. Biotechnology Companies Market, 2018-2030 (USD Million)
5.4. Academic and Research Institutes
5.4.1. Academic and Research Institutes Market, 2018-2030 (USD Million)
Chapter 6. Regional Business Analysis
6.1. Central Lab Market Share By Region, 2023 & 2030
6.2. North America
6.2.1. North America Central lab market, 2018-2030 (USD Million)
6.2.2. U.S.
6.2.2.1. Key Country Dynamics
6.2.2.2. Target Disease Prevalence
6.2.2.3. Competitive Scenario
6.2.2.4. Regulatory Framework
6.2.2.5. Reimbursement Scenario
6.2.2.6. U.S. Central lab market, 2018-2030 (USD Million)
6.2.3. Canada
6.2.3.1. Key Country Dynamics
6.2.3.2. Target Disease Prevalence
6.2.3.3. Competitive Scenario
6.2.3.4. Regulatory Framework
6.2.3.5. Reimbursement Scenario
6.2.3.6. Canada Central lab market, 2018-2030 (USD Million)
6.3. Europe
6.3.1. Europe Central lab market, 2018-2030 (USD Million)
6.3.2. Germany
6.3.2.1. Key Country Dynamics
6.3.2.2. Target Disease Prevalence
6.3.2.3. Competitive Scenario
6.3.2.4. Regulatory Framework
6.3.2.5. Reimbursement Scenario
6.3.2.6. Germany Central lab market, 2018-2030 (USD Million)
6.3.3. UK
6.3.3.1. Key Country Dynamics
6.3.3.2. Target Disease Prevalence
6.3.3.3. Competitive Scenario
6.3.3.4. Regulatory Framework
6.3.3.5. Reimbursement Scenario
6.3.3.6. UK Central lab market, 2018-2030 (USD Million)
6.3.4. France
6.3.4.1. Key Country Dynamics
6.3.4.2. Target Disease Prevalence
6.3.4.3. Competitive Scenario
6.3.4.4. Regulatory Framework
6.3.4.5. Reimbursement Scenario
6.3.4.6. France Central lab market, 2018-2030 (USD Million)
6.3.5. Italy
6.3.5.1. Key Country Dynamics
6.3.5.2. Target Disease Prevalence
6.3.5.3. Competitive Scenario
6.3.5.4. Regulatory Framework
6.3.5.5. Reimbursement Scenario
6.3.5.6. Italy Central lab market, 2018-2030 (USD Million)
6.3.6. Spain
6.3.6.1. Key Country Dynamics
6.3.6.2. Target Disease Prevalence
6.3.6.3. Competitive Scenario
6.3.6.4. Regulatory Framework
6.3.6.5. Reimbursement Scenario
6.3.6.6. Spain Central lab market, 2018-2030 (USD Million)
6.3.7. Denmark
6.3.7.1. Key Country Dynamics
6.3.7.2. Target Disease Prevalence
6.3.7.3. Competitive Scenario
6.3.7.4. Regulatory Framework
6.3.7.5. Reimbursement Scenario
6.3.7.6. Denmark Central lab market, 2018-2030 (USD Million)
6.3.8. Sweden
6.3.8.1. Key Country Dynamics
6.3.8.2. Target Disease Prevalence
6.3.8.3. Competitive Scenario
6.3.8.4. Regulatory Framework
6.3.8.5. Reimbursement Scenario
6.3.8.6. Sweden Central lab market, 2018-2030 (USD Million)
6.3.9. Norway
6.3.9.1. Key Country Dynamics
6.3.9.2. Target Disease Prevalence
6.3.9.3. Competitive Scenario
6.3.9.4. Regulatory Framework
6.3.9.5. Reimbursement Scenario
6.3.9.6. Norway Central lab market, 2018-2030 (USD Million)
6.4. Asia-Pacific
6.4.1. Asia-Pacific Central lab market, 2018-2030 (USD Million)
6.4.2. Japan
6.4.2.1. Key Country Dynamics
6.4.2.2. Target Disease Prevalence
6.4.2.3. Competitive Scenario
6.4.2.4. Regulatory Framework
6.4.2.5. Reimbursement Scenario
6.4.2.6. Japan Central lab market, 2018-2030 (USD Million)
6.4.3. China
6.4.3.1. Key Country Dynamics
6.4.3.2. Target Disease Prevalence
6.4.3.3. Competitive Scenario
6.4.3.4. Regulatory Framework
6.4.3.5. Reimbursement Scenario
6.4.3.6. China Central lab market, 2018-2030 (USD Million)
6.4.4. India
6.4.4.1. Key Country Dynamics
6.4.4.2. Target Disease Prevalence
6.4.4.3. Competitive Scenario
6.4.4.4. Regulatory Framework
6.4.4.5. Reimbursement Scenario
6.4.4.6. India Central lab market, 2018-2030 (USD Million)
6.4.5. South Korea
6.4.5.1. Key Country Dynamics
6.4.5.2. Target Disease Prevalence
6.4.5.3. Competitive Scenario
6.4.5.4. Regulatory Framework
6.4.5.5. Reimbursement Scenario
6.4.5.6. South Korea Central lab market, 2018-2030 (USD Million)
6.4.6. Australia
6.4.6.1. Key Country Dynamics
6.4.6.2. Target Disease Prevalence
6.4.6.3. Competitive Scenario
6.4.6.4. Regulatory Framework
6.4.6.5. Reimbursement Scenario
6.4.6.6. Australia Central lab market, 2018-2030 (USD Million)
6.4.7. Thailand
6.4.7.1. Key Country Dynamics
6.4.7.2. Target Disease Prevalence
6.4.7.3. Competitive Scenario
6.4.7.4. Regulatory Framework
6.4.7.5. Reimbursement Scenario
6.4.7.6. Thailand Central lab market, 2018-2030 (USD Million)
6.5. Latin America
6.5.1. Latin America Central lab market, 2018-2030 (USD Million)
6.5.2. Brazil
6.5.2.1. Key Country Dynamics
6.5.2.2. Target Disease Prevalence
6.5.2.3. Competitive Scenario
6.5.2.4. Regulatory Framework
6.5.2.5. Reimbursement Scenario
6.5.2.6. Brazil Central lab market, 2018-2030 (USD Million)
6.5.3. Mexico
6.5.3.1. Key Country Dynamics
6.5.3.2. Target Disease Prevalence
6.5.3.3. Competitive Scenario
6.5.3.4. Regulatory Framework
6.5.3.5. Reimbursement Scenario
6.5.3.6. Mexico Central lab market, 2018-2030 (USD Million)
6.5.4. Argentina
6.5.4.1. Key Country Dynamics
6.5.4.2. Target Disease Prevalence
6.5.4.3. Competitive Scenario
6.5.4.4. Regulatory Framework
6.5.4.5. Reimbursement Scenario
6.5.4.6. Argentina Central lab market, 2018-2030 (USD Million)
6.6. MEA
6.6.1. MEA Central lab market, 2018-2030 (USD Million)
6.6.2. South Africa
6.6.2.1. Key Country Dynamics
6.6.2.2. Target Disease Prevalence
6.6.2.3. Competitive Scenario
6.6.2.4. Regulatory Framework
6.6.2.5. Reimbursement Scenario
6.6.2.6. South Africa Central lab market, 2018-2030 (USD Million)
6.6.3. Saudi Arabia
6.6.3.1. Key Country Dynamics
6.6.3.2. Target Disease Prevalence
6.6.3.3. Competitive Scenario
6.6.3.4. Regulatory Framework
6.6.3.5. Reimbursement Scenario
6.6.3.6. Saudi Arabia Central lab market, 2018-2030 (USD Million)
6.6.4. UAE
6.6.4.1. Key Country Dynamics
6.6.4.2. Target Disease Prevalence
6.6.4.3. Competitive Scenario
6.6.4.4. Regulatory Framework
6.6.4.5. Reimbursement Scenario
6.6.4.6. UAE Central lab market, 2018-2030 (USD Million)
6.6.5. Kuwait
6.6.5.1. Key Country Dynamics
6.6.5.2. Target Disease Prevalence
6.6.5.3. Competitive Scenario
6.6.5.4. Regulatory Framework
6.6.5.5. Reimbursement Scenario
6.6.5.6. Kuwait Central lab market, 2018-2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Participant’s overview
7.2. Financial performance
7.3. Participant categorization
7.3.1. Market Leaders
7.3.2. Central Lab Market Share Analysis, 2023
7.3.3. Company Profiles
7.3.3.1. ACM Global Laboratories
7.3.3.1.1. Company Overview
7.3.3.1.2. Financial Performance
7.3.3.1.3. Product Benchmarking
7.3.3.1.4. Strategic Initiatives
7.3.3.2. LabConnect
7.3.3.2.1. Company Overview
7.3.3.2.2. Financial Performance
7.3.3.2.3. Product Benchmarking
7.3.3.2.4. Strategic Initiatives
7.3.3.3. Cerba Research
7.3.3.3.1. Company Overview
7.3.3.3.2. Financial Performance
7.3.3.3.3. Product Benchmarking
7.3.3.3.4. Strategic Initiatives
7.3.3.4. Eurofins Scientific
7.3.3.4.1. Company Overview
7.3.3.4.2. Financial Performance
7.3.3.4.3. Product Benchmarking
7.3.3.4.4. Strategic Initiatives
7.3.3.5. Versiti (Cenetron)
7.3.3.5.1. Company Overview
7.3.3.5.2. Financial Performance
7.3.3.5.3. Product Benchmarking
7.3.3.5.4. Strategic Initiatives
7.3.3.6. Medicover Integrated Clinical Services (MICS) (Synevo Central Labs)
7.3.3.6.1. Company Overview
7.3.3.6.2. Financial Performance
7.3.3.6.3. Product Benchmarking
7.3.3.6.4. Strategic Initiatives
7.3.3.7. A.P. Møller Holding A/S (Unilabs)
7.3.3.7.1. Company Overview
7.3.3.7.2. Financial Performance
7.3.3.7.3. Product Benchmarking
7.3.3.7.4. Strategic Initiatives
7.3.3.8. Ampersand Capital Partners (Pacific Biomarkers)
7.3.3.8.1. Company Overview
7.3.3.8.2. Financial Performance
7.3.3.8.3. Product Benchmarking
7.3.3.8.4. Strategic Initiatives
7.3.3.9. Lambda Therapeutic Research Ltd
7.3.3.9.1. Company Overview
7.3.3.9.2. Financial Performance
7.3.3.9.3. Product Benchmarking
7.3.3.9.4. Strategic Initiatives
7.3.3.10. CIRION BioPharma Research Inc.
7.3.3.10.1. Company Overview
7.3.3.10.2. Financial Performance
7.3.3.10.3. Product Benchmarking
7.3.3.10.4. Strategic Initiatives
7.3.4. Strategy Mapping
7.3.4.1. Expansion
7.3.4.2. Acquisition
7.3.4.3. Collaborations
7.3.4.4. Disease Type/Drug Class Launch
7.3.4.5. Partnerships
7.3.4.6. Others
List of Tables
Table 1 List of Abbreviations
Table 2 Global Central Lab Market, by Service, 2018-2030 (USD Million)
Table 3 Global Central Lab Market, by End Use, 2018-2030 (USD Million)
Table 4 Global Central Lab Market, by Region, 2018-2030 (USD Million)
Table 5 North America Central Lab Market, by Country, 2018-2030 (USD Million)
Table 6 North America Central Lab Market, by Service, 2018-2030 (USD Million)
Table 7 North America Central Lab Market, by End Use, 2018-2030 (USD Million)
Table 8 U.S. Central Lab Market, by Service, 2018-2030 (USD Million)
Table 9 U.S. Central Lab Market, by End Use, 2018-2030 (USD Million)
Table 10 Canada Central Lab Market, by Service, 2018-2030 (USD Million)
Table 11 Canada Central Lab Market, by End Use, 2018-2030 (USD Million)
Table 12 Europe Central Lab Market, by Country, 2018-2030 (USD Million)
Table 13 Europe Central Lab Market, by Service, 2018-2030 (USD Million)
Table 14 Europe Central Lab Market, by End Use, 2018-2030 (USD Million)
Table 15 Germany Central Lab Market, by Service, 2018-2030 (USD Million)
Table 16 Germany Central Lab Market, by End Use, 2018-2030 (USD Million)
Table 17 UK Central Lab Market, by Service, 2018-2030 (USD Million)
Table 18 UK Central Lab Market, by End Use, 2018-2030 (USD Million)
Table 19 France Central Lab Market, by Service, 2018-2030 (USD Million)
Table 20 France Central Lab Market, by End Use, 2018-2030 (USD Million)
Table 21 Italy Central Lab Market, by Service, 2018-2030 (USD Million)
Table 22 Italy Central Lab Market, by End Use, 2018-2030 (USD Million)
Table 23 Spain Central Lab Market, by Service, 2018-2030 (USD Million)
Table 24 Spain Central Lab Market, by End Use, 2018-2030 (USD Million)
Table 25 Denmark Central Lab Market, by Service, 2018-2030 (USD Million)
Table 26 Denmark Central Lab Market, by End Use, 2018-2030 (USD Million)
Table 27 Sweden Central Lab Market, by Service, 2018-2030 (USD Million)
Table 28 Sweden Central Lab Market, by End Use, 2018-2030 (USD Million)
Table 29 Norway Central Lab Market, by Service, 2018-2030 (USD Million)
Table 30 Norway Central Lab Market, by End Use, 2018-2030 (USD Million)
Table 31 Asia-Pacific Central Lab Market, by Country, 2018-2030 (USD Million)
Table 32 Asia-Pacific Central Lab Market, by Service, 2018-2030 (USD Million)
Table 33 Asia-Pacific Central Lab Market, by End Use, 2018-2030 (USD Million)
Table 34 China Central Lab Market, by Service, 2018-2030 (USD Million)
Table 35 China Central Lab Market, by End Use, 2018-2030 (USD Million)
Table 36 Japan Central Lab Market, by Service, 2018-2030 (USD Million)
Table 37 Japan Central Lab Market, by End Use, 2018-2030 (USD Million)
Table 38 India Central Lab Market, by Service, 2018-2030 (USD Million)
Table 39 India Central Lab Market, by End Use, 2018-2030 (USD Million)
Table 40 South Korea Central Lab Market, by Service, 2018-2030 (USD Million)
Table 41 South Korea Central Lab Market, by End Use, 2018-2030 (USD Million)
Table 42 Australia Central Lab Market, by Service, 2018-2030 (USD Million)
Table 43 Australia Central Lab Market, by End Use, 2018-2030 (USD Million)
Table 44 Thailand Central Lab Market, by Service, 2018-2030 (USD Million)
Table 45 Thailand Central Lab Market, by End Use, 2018-2030 (USD Million)
Table 46 Latin America Central Lab Market, by Country, 2018-2030 (USD Million)
Table 47 Latin America Central Lab Market, by Service, 2018-2030 (USD Million)
Table 48 Latin America Central Lab Market, by End Use, 2018-2030 (USD Million)
Table 49 Brazil Central Lab Market, by Service, 2018-2030 (USD Million)
Table 50 Brazil Central Lab Market, by End Use, 2018-2030 (USD Million)
Table 51 Mexico Central Lab Market, by Service, 2018-2030 (USD Million)
Table 52 Mexico Central Lab Market, by End Use, 2018-2030 (USD Million)
Table 53 Argentina Central Lab Market, by Service, 2018-2030 (USD Million)
Table 54 Argentina Central Lab Market, by End Use, 2018-2030 (USD Million)
Table 55 Middle East & Africa Central Lab Market, by Service, 2018-2030 (USD Million)
Table 56 Middle East & Africa Central Lab Market, by Service, 2018-2030 (USD Million)
Table 57 Middle East & Africa Central Lab Market, by End Use, 2018-2030 (USD Million)
Table 58 South Africa Central Lab Market, by Service, 2018-2030 (USD Million)
Table 59 South Africa Central Lab Market, by End Use, 2018-2030 (USD Million)
Table 60 Saudi Arabia Central Lab Market, by Service, 2018-2030 (USD Million)
Table 61 Saudi Arabia Central Lab Market, by End Use, 2018-2030 (USD Million)
Table 62 UAE Central Lab Market, by Service, 2018-2030 (USD Million)
Table 63 UAE Central Lab Market, by End Use, 2018-2030 (USD Million)
Table 64 Kuwait Central Lab Market, by Service, 2018-2030 (USD Million)
Table 65 Kuwait Central Lab Market, by End Use, 2018-2030 (USD Million)
List of Figures
Figure 1 Market research process
Figure 2 Information Procurement
Figure 3 Primary Research Pattern
Figure 4 Market Research Approaches
Figure 5 Value Chain-Based Sizing & Forecasting
Figure 6 Market Formulation & Validation
Figure 7 Central Lab Market Segmentation
Figure 8 Market Snapshot, 2023
Figure 9 Market Trends & Outlook
Figure 10 Market Driver Relevance Analysis (Current & Future Impact)
Figure 11 Market Restraint Relevance Analysis (Current & Future Impact)
Figure 12 PESTEL Analysis, By Factor (Political & Legal, Economic and Technological)
Figure 13 Porter’s Five Forces Analysis
Figure 14 Global Central Lab Market: Service Movement Analysis
Figure 15 Global Central Lab Market, by Genetic Services, 2018-2030 (USD Million)
Figure 16 Global Central Lab Market, by Biomarker Services, 2018-2030 (USD Million)
Figure 17 Global Central Lab Market, by Anatomic Pathology/Histology, 2018-2030 (USD Million)
Figure 18 Global Central Lab Market, by Specimen Management & Storage, 2018-2030 (USD Million)
Figure 19 Global Central Lab Market, by Special Chemistry Services, 2018-2030 (USD Million)
Figure 20 Global Central Lab Market, by Others, 2018-2030 (USD Million)
Figure 21 Global Central Lab Market: End-Use Movement Analysis
Figure 22 Global Central Lab Market, by Pharmaceutical Companies 2018-2030 (USD Million)
Figure 23 Global Central Lab Market, by Biotechnology Companies 2018-2030 (USD Million)
Figure 24 Global Central Lab Market, by Academic & Research Institutes, 2018-2030 (USD Million)
Figure 25 Regional Marketplace: Key Takeaways
Figure 26 Regional Outlook, 2023 & 2030
Figure 27 Global Central Lab Market: Region Movement Analysis
Figure 28 North America Central Lab Market, 2018-2030 (USD Million)
Figure 29 U.S. Central Lab Market, 2018-2030 (USD Million)
Figure 30 Canada Central Lab Market, 2018-2030 (USD Million)
Figure 31 Europe Central Lab Market, 2018-2030 (USD Million)
Figure 32 Germany Central Lab Market, 2018-2030 (USD Million)
Figure 33 UK Central Lab Market, 2018-2030 (USD Million)
Figure 34 France Central Lab Market, 2018-2030 (USD Million)
Figure 35 Italy Central Lab Market, 2018-2030 (USD Million)
Figure 36 Spain Central Lab Market, 2018-2030 (USD Million)
Figure 37 Denmark Central Lab Market, 2018-2030 (USD Million)
Figure 38 Sweden Central Lab Market, 2018-2030 (USD Million)
Figure 39 Norway Central Lab Market, 2018-2030 (USD Million)
Figure 40 Asia-Pacific Central Lab Market, 2018-2030 (USD Million)
Figure 41 Japan Central Lab Market, 2018-2030 (USD Million)
Figure 42 China Central Lab Market, 2018-2030 (USD Million)
Figure 43 India Central Lab Market, 2018-2030 (USD Million)
Figure 44 Australia Central Lab Market, 2018-2030 (USD Million)
Figure 45 South Korea Central Lab Market, 2018-2030 (USD Million)
Figure 46 Thailand Central Lab Market, 2018-2030 (USD Million)
Figure 47 Latin America Central Lab Market, 2018-2030 (USD Million)
Figure 48 Brazil Central Lab Market, 2018-2030 (USD Million)
Figure 49 Mexico Central Lab Market, 2018-2030 (USD Million)
Figure 50 Argentina Central Lab Market, 2018-2030 (USD Million)
Figure 51 Middle East and Africa Central Lab Market, 2018-2030 (USD Million)
Figure 52 South Africa Central Lab Market, 2018-2030 (USD Million)
Figure 53 Saudi Arabia Central Lab Market, 2018-2030 (USD Million)
Figure 54 UAE Central Lab Market, 2018-2030 (USD Million)
Figure 55 Kuwait Central Lab Market, 2018-2030 (USD Million)

Companies Mentioned

  • ACM Global Laboratories
  • LabConnect
  • Cerba Research
  • Eurofins Scientific
  • Versiti (Cenetron)
  • Medicover Integrated Clinical Services (MICS) (Synevo Central Labs)
  • A.P. Møller Holding A/S (Unilabs)
  • Ampersand Capital Partners (Pacific Biomarkers)
  • Lambda Therapeutic Research Ltd
  • CIRION BioPharma Research Inc.

Methodology

Loading
LOADING...

Table Information